Relates to the training requirements for prescribers of certain pain medications.
Summary
Bill A01917 seeks to amend the public health law in New York to establish updated training requirements for prescribers of certain pain medications. The bill mandates that the commissioner, in consultation with relevant departments, create and approve standards for coursework or training in pain management, palliative care, and addiction. This training will encompass state and federal requirements for prescribing controlled substances, managing acute pain, and recognizing signs of substance use disorder, among other topics. The bill emphasizes the importance of patient-centered care and considers social determinants of health in its training standards.
Impact
If enacted, this bill will enhance the training requirements for medical professionals who prescribe pain medications, thereby aiming to reduce the risks associated with opioid prescriptions and improve patient care. It will also require that licensed prescribers complete additional training on overdose prevention and the treatment of addiction, which could lead to a more informed healthcare workforce capable of addressing the complexities of pain management and substance use disorders.
Sentiment
The sentiment surrounding Bill A01917 appears to be generally supportive, as it addresses critical issues related to pain management and addiction treatment. However, there may be concerns regarding the implementation of these training requirements and the potential burden on prescribers to comply with new educational standards.
Contention
Notable points of contention may arise from prescribers who feel that the additional training requirements could be burdensome or that they may not adequately address the complexities of prescribing practices. Additionally, there may be differing opinions on the effectiveness of such training in actually reducing addiction rates and improving patient outcomes.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.